Anzeige
Mehr »
Login
Montag, 20.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
44 Leser
Artikel bewerten:
(0)

Congressman Chaka Fattah (PA-02) Visits Israel for International Brain Tech Conference, Diplomatic Meetings

WASHINGTON, Oct. 12, 2013 /PRNewswire-USNewswire/ -- Congressman Chaka Fattah (PA-02) will travel to Israel this Sunday, October 13, where he will deliver a keynote address at Brain Tech Israel 2013, the country's first ever international brain technology conference. Fattah's keynote speech, "Neurotechnology-The Time is Now," will address his work as the architect of the Fattah Neuroscience Initiative (FNI) and provide an update on President Obama's BRAIN Initiative.

Congressman Fattah is the only U.S. elected official invited to address the conference. During the visit-his first to the country-he will also meet with Israeli President Shimon Peres, U.S. Ambassador to Israel Daniel Shapiro, Avi Hasson, Chief Scientist of the Ministry of Economy, and a group of young Israeli entrepreneurs that have business interests in the Philadelphia area.

Fattah has been instrumental in enhancing the US-Israel collaboration in neuroscience and neurotechnology, and the visit is an extension of his effort to increase partnerships between the two countries. The visit will build on Philadelphia and Israel's strong economic ties, as Fattah explores new opportunities for investment and cooperation, especially among his district's hospitals, research universities, and science centers.

To date, he's supported several joint projects between the Philadelphia region and Israel, including the clinical trial of ReWalk (designed in Israel) at Philadelphia's Einstein Medical Center. Since founding FNI in 2011, Fattah has traveled the country engaging stakeholders in dialogue around neuroscience research and funding, highlighting the opportunities for public-private sector collaboration both within the U.S. and worldwide.

Brain Tech Israel brings together government officials, Nobel Prize winners, investors, scientists, entrepreneurs, and leading multinationals to discuss cutting-edge brain technologies from Israel and around the world. Dr. Philip Low, Founder and CEO of NeuroVigil, a San Diego-based company, will deliver the conference's closing keynote. The conference will also award the inaugural $1 million Global B.R.A.I.N. Prize to one of 10 finalists, which include several American researchers and companies. A full conference schedule and details can be found at: http://conference.israelbrain.org/program/.

For additional information on the Fattah Neuroscience Initiative, please visit: http://fattah.house.gov/uploads/Fattah%20Neuroscience%20Initiative_Press%20Kit.pdf

WHO:

Congressman Chaka Fattah (PA-02)



WHAT:

Fattah Visit to Israel will include:


  • Keynote Speech at Brain Tech Israel 2013

  • Diplomatic meetings with Israeli President Shimon Peresand U.S. Ambassador Daniel Shapiro

  • Policy meetings with Avi Hasson, Chief Scientist of the Ministry of Economy and young Israeli entrepreneurs in tech and innovation fields

WHEN:

Sunday, October 13 - Tuesday, October 15, 2013



DETAILS:

For additional trip details, or to arrange an interview, please email Allyson.Freeman@mail.house.gov

SOURCE Office of Congressman Chaka Fattah

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.